Articles

Interview with Stemson Therapeutics CEO Geoff Hamilton

September 23, 2021 /

Follicle Thought is very pleased to share this exclusive interview with the CEO of Stemson Therapeutics, Geoff Hamilton. Follicle Thought: Hi Geoff, thank you for doing this interview with Follicle Thought. To start, could you please tell us about how you met Dr. Alexey Terskikh and went on to become Stemson’s CEO? Geoff Hamilton: Well, thank…

Read More

Kintor’s KX-826 Pyrilutamide Meets Goal In Phase 2 Trial

September 8, 2021 /

Kintor Pharmaceutical of China brings us some timely good news today regarding its lead candidate drug KX-826 for the treatment of androgenetic alopecia. Phase 3 Will Be Soon A well respected company in the hair growth industry, Kintor Pharmaceutical, continues to outpace the competition. In a press release issued today, the company announced that KX-826…

Read More

Q3 2021 New Companies: AddPharma, Novaliq, and Rizn

August 31, 2021 /

This article covers a few companies not previously discussed online and recent happenings in hair growth related news. AddPharma of Korea Where else would new hair growth medicine be coming out of but Korea? In the case of AddPharma, it’s a mixture of “old and new”, but we’ll take it. AddPharma is a pharmaceutical company…

Read More

Alopecia Areata Treatment Pipeline 2023

August 6, 2021 /

In this article we will cover the most prominent therapeutic candidates in the alopecia areata treatment industry in 2023. Frontrunners To Market In June 2022,  Eli Lilly/Incyte received the FDA’s first ever approval for a systemic treatment for alopecia areata with their drug Olumiant. Alopecia areata, an auto-immune disorder which results in patchy and sometimes…

Read More

Stemson Therapeutics Raises $15M To Bolster Hair Regeneration Efforts

July 15, 2021 /

The company founded on Alexey Terskikh’s hair multiplication research at the Sanford Burnham Prebys Institute has not had a problem raising capital since its inception a few years ago. In a press release issued today, July, 15, 2021, Stemson Therapeutics announced the closing of a $15 million Series A financing round. DCVC-Bio and Genoa Ventures…

Read More

David Sinclair Is Working On Hair Regeneration

June 26, 2021 /

Perhaps the world’s most famous aging researcher, Dr. David Sinclair of Harvard University, recently revealed that his lab is working on an advanced method for hair restoration. The Sinclair Lab at  Harvard Medical School Hair Growth Research Located in Boston, MA, The Sinclair Lab conducts cutting-edge research on the mechanisms of biological aging. The laboratory’s…

Read More

Turn Biotechnologies: mRNA Hair Growth Therapy

June 15, 2021 /

Today, I am pleased to introduce yet another company entering the hair growth treatment industry, Turn Biotechnologies. The company is creating therapies which restore human cells to a more youthful state and has a program targeting skin and hair. Turn Biotechnologies is one of the latest companies to make waves in the anti-aging/aging-reversal sector. The…

Read More

TechnoDerma Medicines Enters Clinical Trial & More

May 24, 2021 /

This article continues the recent trend of new company announcements within the hair growth treatment industry. Even better, today’s news involves a new drug entering a phase 1 clinical trial in the US. New Drug Candidate TDM-105795 TechnoDerma Medicines Inc. of China is an early-stage biotech company based in the Zhejiang Province of China. The…

Read More

Verteporfin Could Create Scarless Hair Transplant Surgery

May 11, 2021 /

New research from Stanford University may have uncovered a new useful application for hair restoration surgery. Stanford Stops The Engrailed-1 Last month in April, a research team from Stanford University headed by Dr. Michael Longaker, published a study on scarless wound healing which captured mainstream attention. The peer-reviewed study titled “Preventing Engrailed-1 activation in fibroblasts yields…

Read More

Follicum Shares Results From Phase 2a Trial Of Topical FOL-005

May 6, 2021 /

On May 6, 2021 the Swedish biotech company Follicum announced results from its pivotal phase 2 trial which represented the first time its candidate peptide FOL-005 was tested topically to treat male pattern baldness. FOL-005 Grew Hair, But Not Quite Enough To keep things succinct, FOL-005 did not reach its goal in the phase 2…

Read More

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.